Payment overview · 2025
General Payments
$116.36
6 reported records · 4 companies
Healthcare provider profile · identity verified
Frank Parma, MD
Allopathic & Osteopathic Physicians|Family Medicine · VICTORIA, TX · NPI 1427078724
Verified facts
What the public records show
CMS Open Payments records show Frank Parma, MD received $116.36 in general payments during 2025 across 6 reported records.
Novo Nordisk Inc accounted for 33.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 8 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Trelegy Ellipta by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 76 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 149 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 32 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $38.77 | 33.3% | 2 | 2025 |
| Antares Pharma, Inc. | Unresolved — no canonical attribution shown | $37.95 | 32.6% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $23.38 | 20.1% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $16.26 | 14.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $116.36 | 6 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| XYOSTED Normalized: xyosted |
Drug | Antares Pharma, Inc. | $37.95 | 2 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $23.38 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $23.38 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $22.53 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $22.53 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $16.26 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $16.26 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $16.24 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 76 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
76 | 12 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
149 | 27 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
32 | 31 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Amlodipine Besylate | Amlodipine Besylate | 774 | 209 |
| Atorvastatin Calcium | Atorvastatin Calcium | 749 | 196 |
| Levothyroxine Sodium | Levothyroxine Sodium | 594 | 154 |
| Losartan Potassium | Losartan Potassium | 503 | 128 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 442 | 131 |
| Lisinopril | Lisinopril | 406 | 108 |
| Pantoprazole Sodium | Pantoprazole Sodium | 330 | 96 |
| Metoprolol Succinate | Metoprolol Succinate | 317 | 86 |
| Furosemide | Furosemide | 286 | 64 |
| Meloxicam | Meloxicam | 282 | 78 |
| Metformin Hcl | Metformin Hcl | 276 | 73 |
| Gabapentin | Gabapentin | 252 | 69 |
| Simvastatin | Simvastatin | 244 | 58 |
| Tamsulosin Hcl | Tamsulosin Hcl | 244 | 72 |
| Famotidine | Famotidine | 205 | 55 |
| Irbesartan | Irbesartan | 199 | 55 |
| Mounjaro | Tirzepatide | 190 | 35 |
| Pravastatin Sodium | Pravastatin Sodium | 190 | 47 |
| Glipizide | Glipizide | 181 | 50 |
| Metformin Hcl Er | Metformin Hcl | 172 | 52 |
| Prednisone | Prednisone | 172 | 119 |
| Hydrochlorothiazide | Hydrochlorothiazide | 166 | 51 |
| Alprazolam | Alprazolam | 161 | 32 |
| Potassium Chloride | Potassium Chloride | 160 | 32 |
| Montelukast Sodium | Montelukast Sodium | 159 | 42 |
| Azithromycin | Azithromycin | 153 | 115 |
| Eliquis | Apixaban | 149 | 27 |
| Tramadol Hcl | Tramadol Hcl | 148 | 24 |
| Allopurinol | Allopurinol | 134 | 33 |
| Atenolol | Atenolol | 131 | 29 |
| Pioglitazone Hcl | Pioglitazone Hcl | 130 | 36 |
| Alendronate Sodium | Alendronate Sodium | 123 | 31 |
| Escitalopram Oxalate | Escitalopram Oxalate | 123 | 30 |
| Metoprolol Tartrate | Metoprolol Tartrate | 123 | 33 |
| Zolpidem Tartrate | Zolpidem Tartrate | 114 | 25 |
| Omeprazole | Omeprazole | 111 | 35 |
| Jardiance | Empagliflozin | 108 | 29 |
| Januvia | Sitagliptin Phosphate | 105 | 20 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 102 | 40 |
| Clopidogrel | Clopidogrel Bisulfate | 97 | 26 |
| Trulicity | Dulaglutide | 95 | 16 |
| Sertraline Hcl | Sertraline Hcl | 92 | 23 |
| Memantine Hcl | Memantine Hcl | 86 | 19 |
| Pregabalin | Pregabalin | 84 | 18 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 83 | 20 |
| Donepezil Hcl | Donepezil Hcl | 81 | 19 |
| Ezetimibe | Ezetimibe | 81 | 22 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 81 | 21 |
| Ozempic | Semaglutide | 76 | 12 |
| Clonazepam | Clonazepam | 74 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 72 | 20 |
| Glipizide Er | Glipizide | 70 | 23 |
| Celecoxib | Celecoxib | 69 | 18 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 68 | 17 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 66 | 20 |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 65 | 52 |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 63 | 18 |
| Finasteride | Finasteride | 63 | 16 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 62 | 14 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 59 | 17 |
| Synthroid | Levothyroxine Sodium | 58 | 16 |
| Valsartan | Valsartan | 56 | 16 |
| Farxiga | Dapagliflozin Propanediol | 53 | 13 |
| Hydralazine Hcl | Hydralazine Hcl | 53 | 18 |
| Labetalol Hcl | Labetalol Hcl | 53 | 13 |
| Fluticasone Propionate | Fluticasone Propionate | 52 | 23 |
| Spironolactone | Spironolactone | 50 | 16 |
| Methylprednisolone | Methylprednisolone | 49 | 38 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 49 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 46 | 23 |
| Trazodone Hcl | Trazodone Hcl | 43 | suppressed |
| Lorazepam | Lorazepam | 42 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 42 | 12 |
| Xarelto | Rivaroxaban | 41 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 39 | 17 |
| Lansoprazole | Lansoprazole | 39 | 13 |
| Cefdinir | Cefdinir | 37 | 35 |
| Fenofibric Acid | Fenofibric Acid (Choline) | 37 | 11 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 36 | 32 |
| Duloxetine Hcl | Duloxetine Hcl | 35 | 14 |
| Levofloxacin | Levofloxacin | 35 | 32 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 35 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 35 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 34 | suppressed |
| Cephalexin | Cephalexin | 33 | 23 |
| Paroxetine Hcl | Paroxetine Hcl | 33 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 33 | 12 |
| Myrbetriq | Mirabegron | 32 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 32 | 31 |
| Terazosin Hcl | Terazosin Hcl | 32 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 31 | suppressed |
| Chlorthalidone | Chlorthalidone | 30 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 30 | 22 |
| Ramipril | Ramipril | 29 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 29 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 28 | suppressed |
| Telmisartan | Telmisartan | 28 | suppressed |
| Bydureon Bcise | Exenatide Microspheres | 27 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 27 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 27 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 27 | 12 |
| Sumatriptan Succinate | Sumatriptan Succinate | 27 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 26 | 23 |
| Novolog Mix 70-30 Flexpen | Insulin Aspart Prot/Insuln Asp | 26 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 26 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 25 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 25 | suppressed |
| Verapamil Er | Verapamil Hcl | 25 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 23 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 23 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 22 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 22 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 22 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 22 | 16 |
| Propranolol Hcl Er | Propranolol Hcl | 22 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 21 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 21 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 20 | suppressed |
| Nitroglycerin | Nitroglycerin | 20 | suppressed |
| Bupropion Xl | Bupropion Hcl | 19 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 19 | suppressed |
| Nystatin | Nystatin | 19 | 12 |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 19 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 19 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 18 | suppressed |
| Dabigatran Etexilate | Dabigatran Etexilate Mesylate | 18 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 18 | suppressed |
| Acyclovir | Acyclovir | 17 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 17 | suppressed |
| Fluconazole | Fluconazole | 17 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 17 | suppressed |
| Torsemide | Torsemide | 17 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 17 | suppressed |
| Glimepiride | Glimepiride | 16 | suppressed |
| Invokana | Canagliflozin | 16 | suppressed |
| Levetiracetam | Levetiracetam | 16 | suppressed |
| Carvedilol | Carvedilol | 15 | suppressed |
| Dutasteride | Dutasteride | 15 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 15 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 15 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 15 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 15 | 14 |
| Aripiprazole | Aripiprazole | 14 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 14 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 13 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 13 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 13 | suppressed |
| Estradiol | Estradiol | 13 | suppressed |
| Spironolactone-Hctz | Spironolact/Hydrochlorothiazid | 13 | suppressed |
| Topiramate | Topiramate | 13 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 12 | suppressed |
| Colchicine | Colchicine | 12 | suppressed |
| Digoxin | Digoxin | 12 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 12 | suppressed |
| Fiasp Flextouch | Insulin Aspart (Niacinamide) | 12 | suppressed |
| Mesalamine Er | Mesalamine | 12 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 12 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 12 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 12 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 12 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Breyna | Budesonide/Formoterol Fumarate | 11 | suppressed |
| Carbamazepine Er | Carbamazepine | 11 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 11 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 11 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 11 | suppressed |
| Mupirocin | Mupirocin | 11 | suppressed |
| Naproxen | Naproxen | 11 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 11 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $116.36 · 6 records | Novo Nordisk Inc | AREXVY, NURTEC ODT, Ozempic, Rybelsus, SHINGRIX, Wegovy, XYOSTED, ZAVZPRET | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with GlaxoSmithKline, LLC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error